Emergent BioSolutions Inc. 8-K

What Happened

• Emergent BioSolutions Inc. announced financial and operating results for the quarter ended March 31, 2026 via a press release issued April 30, 2026. The press release is furnished as Exhibit 99.1 to the Form 8-K.
• The company will host a conference call to discuss the quarterly results and has posted earnings presentation slides on its website; those slides are furnished as Exhibit 99.2 to the Form 8-K. The Form 8-K was signed by Richard S. Lindahl, Executive VP and Chief Financial Officer, on April 30, 2026.

Key Details

• Date of filing/announcement: April 30, 2026.
• Reporting period: Quarter ended March 31, 2026 (Q1 2026).
• Materials provided: Press release (Exhibit 99.1) and Earnings Call Slides (Exhibit 99.2).
• Disclosure note: The press release and slides are furnished (not “filed”) and are not incorporated by reference into other SEC filings except where expressly stated.

Why It Matters

• Earnings releases and the accompanying call/slides are the primary source for Q1 metrics—revenue, net income, cash flow and any updated guidance—that investors use to assess short-term performance and revise models.
• Because the materials are furnished (rather than filed), they are included for investor information but are not subject to the same Section 18 liabilities or automatic incorporation into other SEC filings. Investors should review the press release and slides on the company website for the specific quarterly revenue and operating figures and listen to the earnings call for management commentary.